ERBB2 and breast adenocarcinoma: Collectively each of these sets of cell-ELISA findings serve to validate the retained selective binding-avidity of gemcitabine-(C4-amide)-[anti-EGFR] and epirubicin-(C3-amide)-[anti-HER2/neu] for over-expressed EGFR (2.2 × 105 per cell) and highly over-expressed HER2/neu (1 × 106 per cell) trophic receptor sites on the exterior surface membrane of mammary adenocarcinoma (SKBr-3) populations (Figure.